Transcenta Holding Limited

Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacture, and commercialization of drugs. Formerly known as MabSpace International Limited, the company changed its name to Transcenta Holding Limited in June 2019. It was incorporated in 2010 and is headquartered in Suzhou, China. Transcenta Holding Limited is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D, and manufacturing. The company develops various drugs for unmet medical needs, including MSB2311, TST001, TST005, TST002 (Blosozumab), TST004, TST010, TST003, TST006, TST008, MSB0254, TST012, TST013, and TST801. It has partnerships and collaborations with companies and institutions like Bristol Myers Squibb, Eli Lilly & Company, Alebund Pharmaceuticals, Dana Farber Cancer Institute, John Hopkins University, and Merck KGaA.